A Director at Arrowhead Research (NASDAQ: ARWR) is Selling Shares

By Carrie Williams

Yesterday, a Director at Arrowhead Research (ARWRResearch Report), Douglas Given, sold shares of ARWR for $1.25M.

Following Douglas Given’s last ARWR Sell transaction on August 19, 2014, the stock climbed by 4.9%.

See today’s analyst top recommended stocks >>

Based on Arrowhead Research’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $34.66 million and quarterly net profit of $12.04 million. In comparison, last year the company earned revenue of $3.51 million and had a GAAP net loss of $13.2 million. Currently, Arrowhead Research has an average volume of 2.05M. The Company has a Price to Book ratio of 10.3056.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $23.13, reflecting a 20.8% upside.

The insider sentiment on Arrowhead Research has been negative according to 41 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Douglas Given’s trades have generated a 30.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.